Our vision is a world where every cancer patient receives the right therapy.
Our mission is to help the advancement of cancer precision medicine.
We empower healthcare providers with CE/IVD-certified solutions from the tissue handling to the data analysis step of the diagnostic process.
CE-IVD software for analyses of sequencing data from tumors to guide the use of targeted cancer therapies and immuno-checkpoint inhibitors
Fully automated CE-IVD extraction solutions for DNA and RNA without manual reagent handling
Helping our customers to set their workflows for sample isolation and data analysis
Oncodia is an innovative Medical Technology company based in Uppsala, Sweden. We are committed to providing in vitro diagnostic products that consistently meet customer needs, enhance patient treatment outcomes and adhere to regulatory and statutory requirements. Oncodia provides CE/IVD software for precision cancer medicine as well as CE/IVD products for DNA/RNA isolation from diagnostic tissue specimens. Our focus is to supply clinical pathology and oncology with the right solutions for optimal molecular diagnostics of solid tumors.
Oncodia has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 876876
On March 15, 2019, Oncodia entered an exclusive, worldwide agreement with Temasek Life Science Laboratories, Singapore (TLL), on the commercialization of TLL’s patented PBR pattern
Following the Seed Round, the Board of Directors has been extended with senior expertise in medical device commercialization. Erik Hedlund, Chairman of Nolsterby Invest AB,
In a competitive call for supporting product development and accelerating market launch, Oncodia has been was awarded an EIT Health Headstart grant of €50.000. The
Improving the use of advanced cancer drugs by providing healthcare systems with solutions for highly accurate mutation detection.